SKIN

+ Watchlist + Portfolio

The Beauty Health Company

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.59
52-Week Range: $0.55 – $2.69
Market Cap: $81.99M
P/E (TTM): —
EPS (TTM): -0.24
Dividend Yield: —

Advanced Metrics

Price/Book: 1.47
PEG Ratio: 0.93
Return on Equity: -43.89%
Return on Assets: -0.54%
Gross Margin: 66.35%
Operating Margin: 4.95%
Profit Margin: -9.80%
Current Ratio: 1.75
Debt/Equity: 6.61
Total Debt: $367.04M
Free Cash Flow: $27.48M
Revenue Growth: -7.80%
Earnings Growth: —
Enterprise Value: $244.96M

SKIN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$365.88M	$397.99M	$334.29M	$300.79M
Cost of Revenue	$117.10M	$242.88M	$152.00M	$104.43M
Gross Profit	$248.78M	$155.11M	$182.30M	$196.36M
Research & Development	$8.44M	$10.10M	$6.30M	$5.63M
Selling, General & Admin	$266.18M	$275.93M	$243.77M	$211.54M
Operating Expenses	$274.62M	$286.03M	$250.07M	$217.17M
Operating Income	-$25.84M	-$130.92M	-$67.77M	-$20.80M
EBITDA	$81.60M	-$53.56M	$14.54M	$38.74M
Pretax Income	$45.34M	-$101.89M	-$29.55M	-$5.94M
Income Tax	$1.11M	-$1.77M	-$452.00K	$3.58M
Net Income	$44.22M	-$100.12M	-$29.10M	-$9.52M
Diluted EPS	0.23	-0.76	-0.23	-0.16
Diluted Shares	148.51M	131.68M	123.83M	135.80M

SKIN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$568.20M	$523.02M	$370.06M	$232.67M
Receivables	$77.77M	$55.03M	$28.46M	$23.44M
Inventory	$109.66M	$91.32M	$69.11M	$48.01M
Current Assets	$783.27M	$698.25M	$477.12M	$309.52M
Total Assets	$1.00B	$929.11M	$685.68M	$499.80M
Current Liabilities	$71.71M	$115.01M	$68.15M	$186.28M
Long-Term Debt	$734.14M	$738.37M	$552.20M	$240.43M
Total Debt	$751.79M	$752.29M	$568.16M	$378.76M
Total Liabilities	$836.03M	$869.72M	$633.88M	$438.75M
Retained Earnings	-$378.75M	-$478.87M	-$507.96M	-$517.48M
Shareholders' Equity	$167.05M	$59.39M	$51.80M	$61.06M
Working Capital	$711.56M	$583.24M	$408.97M	$123.24M
Net Debt	$165.95M	$215.35M	$182.13M	$131.72M

SKIN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$106.60M	$21.75M	$16.13M	$37.48M
Capital Expenditure	-$17.39M	-$13.05M	-$6.79M	-$5.16M
Free Cash Flow	-$123.99M	$8.70M	$9.34M	$32.32M
Depreciation & Amortisation	$22.87M	$34.67M	$33.68M	$25.35M
Stock-Based Compensation	$28.50M	$22.54M	$26.70M	$14.82M
Investing Cash Flow	-$18.87M	-$31.51M	-$6.79M	-$5.16M
Financing Cash Flow	-$205.24M	-$37.45M	-$158.34M	-$174.93M
Share Repurchases	-$160.00M	-$32.40M	$0.00	$0.00
Net Change in Cash	-$330.71M	-$47.20M	-$149.00M	-$142.60M

SKIN Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$78.19M	$70.66M	$82.37M	$64.91M	$72.11M
Cost of Revenue	$29.07M	$25.02M	$29.33M	$20.47M	$22.77M
Gross Profit	$49.11M	$45.63M	$53.04M	$44.44M	$49.34M
Research & Development	$1.25M	$1.70M	$1.68M	$1.10M	$1.41M
Selling, General & Admin	$50.56M	$50.18M	$51.20M	$45.14M	$44.36M
Operating Expenses	$51.81M	$51.88M	$52.88M	$46.24M	$45.77M
Operating Income	-$2.70M	-$6.24M	$162.00K	-$1.80M	$3.57M
EBITDA	$28.26M	$4.10M	$6.92M	$4.87M	$10.11M
Pretax Income	$18.72M	-$10.64M	-$4.81M	-$6.81M	-$1.46M
Income Tax	-$993.00K	$386.00K	$3.30M	-$184.00K	$1.21M
Net Income	$19.71M	-$11.03M	-$8.10M	-$6.63M	-$2.67M
Diluted EPS	0.03	-0.09	-0.06	-0.05	-0.02
Diluted Shares	140.29M	126.89M	127.44M	131.40M	129.60M

SKIN Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$212.00M	$219.40M	$232.67M	$204.36M	$206.07M
Receivables	$27.13M	$25.39M	$23.44M	$20.25M	$19.63M
Inventory	$59.19M	$56.15M	$48.01M	$47.69M	$46.84M
Current Assets	$306.11M	$308.37M	$309.52M	$277.69M	$295.24M
Total Assets	$507.56M	$503.64M	$499.80M	$473.23M	$486.57M
Current Liabilities	$59.44M	$61.90M	$186.28M	$155.20M	$168.20M
Long-Term Debt	$363.10M	$363.39M	$240.43M	$241.28M	$242.12M
Total Debt	$376.73M	$378.98M	$378.76M	$367.13M	$367.04M
Total Liabilities	$433.56M	$437.98M	$438.75M	$417.99M	$431.00M
Retained Earnings	-$498.35M	-$509.38M	-$517.48M	-$524.11M	-$526.78M
Shareholders' Equity	$74.00M	$65.66M	$61.06M	$55.24M	$55.57M
Working Capital	$246.67M	$246.46M	$123.24M	$122.49M	$127.04M
Net Debt	$151.10M	$143.99M	$131.72M	$139.86M	$139.13M

SKIN Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$9.65M	$9.65M	$15.20M	-$5.55M	$2.67M
Capital Expenditure	-$1.55M	-$1.08M	-$1.38M	-$1.65M	-$1.21M
Free Cash Flow	$8.09M	$8.56M	$13.81M	-$7.20M	$1.47M
Depreciation & Amortisation	$5.40M	$8.43M	$5.35M	$5.34M	$5.27M
Stock-Based Compensation	$5.31M	$2.46M	$3.58M	$2.08M	$2.90M
Investing Cash Flow	-$1.55M	-$1.08M	-$1.38M	-$1.65M	-$1.21M
Financing Cash Flow	-$173.36M	-$803.00K	-$512.00K	-$20.91M	-$224.00K
Net Change in Cash	-$165.27M	$7.76M	$13.30M	-$28.11M	$1.24M

Market Snapshot

About

The Beauty Health Company is a global category-creating company that develops and delivers beauty health experiences through its flagship Hydrafacial brand. The company provides skin health solutions through proprietary technology, clinical-grade serums, and a network of aesthetic professionals.